Alliance Global analyst Scott Henry raised the firm’s price target on Evogene (EVGN) to $2.25 from $1.75 and keeps a Buy rating on the shares. The company has pivoted its model to focus on its ChemPass AI engine for designing small molecules for the pharmaceutical and agricultural industries, the analyst tells investors in a research note. The firm sees Evogene signing 10 partnerships by early 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVGN:
- Evogene Faces Nasdaq Minimum Bid Price Deficiency, Granted Cure Period to September 2026
- Evogene receives Nasdaq minimum bid price notification
- Evogene files to sell 5.08M ordinary shares for holders
- Evogene price target lowered to $1.75 from $2.50 at Alliance Global
- Evogene Earnings Call: AI Ambition Meets Cash Reality